Branches of biology

NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019

Tuesday, November 12, 2019 - 6:30am

The results also show that the combination that included NBTXR3 and anti-PD-1 has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.

Key Points: 
  • The results also show that the combination that included NBTXR3 and anti-PD-1 has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.
  • This opens the possibility for radiation de-escalation, meaning the amount of radiation therapy could be reduced without decreasing efficacy.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix.
  • The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS

Tuesday, November 12, 2019 - 6:00am

Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement.

Key Points: 
  • Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement.
  • In conjunction with todays alliance, MEDIPAL has decided to increase its shareholdings in the Promethera Group.
  • Promethera completed the recruitment of 24 patients in its Phase 2a study in Acute-on-chronic liver failure (ACLF) in July 2019.
  • As a holding company, MEDIPAL controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.

DietDemand’s Emotional Eating Focus Helps Clients Understand Why Many Weight Loss Diets Don’t Work

Tuesday, November 12, 2019 - 6:00am

Fortunately, DietDemand has created a customized medical weight loss program focused on helping individuals overcome the real problem, stress-based emotional eating.

Key Points: 
  • Fortunately, DietDemand has created a customized medical weight loss program focused on helping individuals overcome the real problem, stress-based emotional eating.
  • Our doctor created and supervised medical weight loss plans combat emotional eating in many different ways, ranging from simple doctor supervision and evaluation to powerful prescription weight loss aids specifically designed to address the causes of emotional eating.
  • Our clients who utilize our unique medical weight loss system experience:
    Want to get personalized consultations from a certified weight loss specialist?
  • For over a decade, DietDemand has produced a sophisticated, doctor designed weight loss program that addresses each individual specific health need to promote fast, safe and long-term weight loss.

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting

Tuesday, November 12, 2019 - 6:00am

( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Companys Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting , which is hosted by the Israel Stem Cell Society .

Key Points: 
  • ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Companys Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting , which is hosted by the Israel Stem Cell Society .
  • Ralph Kern, MD, MHSc, said: I welcome the opportunity to participate in the 7th International Stem Cell Meeting where I will share the advances BrainStorm has made with NurOwn.
  • It is a privilege to participate and to exchange ideas with many of the international scientific leaders in stem cell research.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

First Patient in CytoDyn’s Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

Tuesday, November 12, 2019 - 1:02am

Circulating tumor cells (CTC) in the patients blood decreased significantly after leronlimab therapy at both two-week and five-week time points.

Key Points: 
  • Circulating tumor cells (CTC) in the patients blood decreased significantly after leronlimab therapy at both two-week and five-week time points.
  • Moreover, the reduction of CCR5 expression on EMT cells may prove to be significant, as high CCR5 expression is believed to be crucial for metastases.
  • The treatment of mTNBC with leronlimab in this Phase 1b/2 trial is in addition to metastatic breast cancer (MBC) patients treated with leronlimab under an emergency use IND.
  • Although these are early results in our first patient, we are encouraged by the reduction in both CTC and tumor size.

Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

Monday, November 11, 2019 - 9:15pm

SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.

Key Points: 
  • SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.
  • In addition, we announced last week that we initiated a Phase III program to study SPN-812 in the adult ADHD patient population.
  • SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Global Design Contest Awards ULiSSES™ Medical Device Grand Prize

Monday, November 11, 2019 - 9:12pm

ULiSSES, a first-of-its-kind medical device, created by Vascular Perfusion Solutions, Inc. (VPS) has been selected as the Grand Prize winner in the 2019 "Create the Future" Design Contest.

Key Points: 
  • ULiSSES, a first-of-its-kind medical device, created by Vascular Perfusion Solutions, Inc. (VPS) has been selected as the Grand Prize winner in the 2019 "Create the Future" Design Contest.
  • VPS accepted the grand prize along with a $20,000 cash award in New York City on November 8, 2019.
  • View the full release here: https://www.businesswire.com/news/home/20191111005641/en/
    (L-R) Vascular Perfusion Solutions (VPS) Tom DeBrooke, Leonid Bunegin and Rafael Veraza accept the grand prize in the "Create the Future" Design Contest for their creation of ULiSSES, a first-of-its-kind medical device.
  • The ULiSSES device can also operate as a bioreactor, for example, to potentially grow new skin for burn victims.

Access-Power, Inc. Announces the Filing of a Trademark with the United States Patent and Trademark Office for a Method and Delivery of Marijuana and Marijuana Clones called Clones by Drones™

Monday, November 11, 2019 - 8:34pm

GRAND HAVEN, Mich., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Access-Power, Inc., (ACCR or the Company), a Grand Haven based Medical Marijuana Clone corporation announces the Filing of a Trademark with the United States Patent and Trademark Office for a Method and Delivery of Marijuana and Marijuana Clones called Clones by Drones.

Key Points: 
  • GRAND HAVEN, Mich., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Access-Power, Inc., (ACCR or the Company), a Grand Haven based Medical Marijuana Clone corporation announces the Filing of a Trademark with the United States Patent and Trademark Office for a Method and Delivery of Marijuana and Marijuana Clones called Clones by Drones.
  • The filing is complete, and is in the process of being electronically filed with the USPTO.
  • Patrick J. Jensen commented, We at Access-Power, Inc. are delighted to announce the filing for our new futuristic service called Clones by Drones.
  • We are in development of a new service trademarked under the brand name, Clones by Drones, a method for delivering marijuana and marijuana clones online across the country.

Global Epigenetics Market by Product, Application, Technology & Region 2019-2025 - ResearchAndMarkets.com

Monday, November 11, 2019 - 6:00pm

The "Global Epigenetics Market, By Product, Application, Technology, By Region, Growth Potential, Trends Analysis, Competitive Market Size and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Epigenetics Market, By Product, Application, Technology, By Region, Growth Potential, Trends Analysis, Competitive Market Size and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Epigenetics Market is expected to grow with a significant rate during the forecast period 2018-2025 owing to the increasing demand for epigenetics technology for curbing out cancer-related diseases.
  • Rapid advancements in gene technology and advantages of R&D in cost-effective & efficient for less labor intensive will boost Epigenetics market in the upcoming year.
  • On the basis of Technology Type, the global Epigenetics market has been segmented into DNA Methylation, Histone Modification, and others.

Anatomic Pathology Market - Global Forecast to 2024: High Incidence of Cancer and Other Target Diseases Drives Growth - ResearchAndMarkets.com

Monday, November 11, 2019 - 3:46pm

The growth in this market is attributed to the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine.

Key Points: 
  • The growth in this market is attributed to the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine.
  • In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.
  • Disease diagnosis segment accounted for the larger share of the anatomic pathology market, by application, in 2018
    Based on application, the anatomic pathology market is segmented into disease diagnosis and medical research.
  • Geographically, the anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.